Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Among authors: keler t. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31. Cancer Immunol Immunother. 2019. PMID: 30382327
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
Thomas LJ, Vitale L, O'Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC Jr, Keler T. Thomas LJ, et al. Among authors: keler t. Mol Cancer Ther. 2016 Dec;15(12):2946-2954. doi: 10.1158/1535-7163.MCT-16-0393. Epub 2016 Sep 26. Mol Cancer Ther. 2016. PMID: 27671527
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA, He LZ, Thomas LJ, Wasiuk A, O'Neill T, Widger J, Crocker A, Mills-Chen L, Forsberg E, Weidlick J, Patterson C, Hammond RA, Boyer J, Sisson C, Alvarado D, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Among authors: keler t. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. doi: 10.1007/s00262-020-02610-y. Epub 2020 May 25. Cancer Immunol Immunother. 2020. PMID: 32451681 Free PMC article.
Development of antibody-targeted vaccines.
Keler T, He L, Graziano RF. Keler T, et al. Curr Opin Mol Ther. 2005 Apr;7(2):157-63. Curr Opin Mol Ther. 2005. PMID: 15844624 Review.
Antigenic targeting of the human mannose receptor induces tumor immunity.
He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, O'Neill T, Petromilli C, Zhang HF, Lopez J, Rohrer D, Keler T, Clynes R. He LZ, et al. Among authors: keler t. J Immunol. 2007 May 15;178(10):6259-67. doi: 10.4049/jimmunol.178.10.6259. J Immunol. 2007. PMID: 17475854
115 results